GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argos Therapeutics Inc (FRA:77AA) » Definitions » Research & Development

Argos Therapeutics (FRA:77AA) Research & Development : €14.15 Mil (TTM As of Sep. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Argos Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Argos Therapeutics's Research & Development for the three months ended in Sep. 2018 was €2.85 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2018 was €14.15 Mil.

Argos Therapeutics Research & Development Historical Data

The historical data trend for Argos Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argos Therapeutics Research & Development Chart

Argos Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Research & Development
Get a 7-Day Free Trial Premium Member Only 17.51 36.90 56.97 36.32 18.30

Argos Therapeutics Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.82 3.44 4.50 3.36 2.85

Argos Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was €14.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argos Therapeutics  (FRA:77AA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Argos Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of Argos Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Argos Therapeutics (FRA:77AA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argos Therapeutics Inc (FRA:77AA) » Definitions » Research & Development
Comparable Companies
PTEO NSPX CTBO PRTX BOM:524604 GWSN CBDC ATMS HSTC AKAOQ XSAT:EURI B CAPS MBVXQ TSXV:PBS WAR:PFM TIKRF BOM:506365 BOM:532041 GOVX BOM:524796
Traded in Other Exchanges
N/A
Address
4233 Technology Drive, Durham, NC, USA, 27704
Website
http://www.argostherapeutics.com
Argos Therapeutics Inc is a biopharmaceutical company. It is engaged in the development and commercialization of immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis.

Argos Therapeutics (FRA:77AA) Headlines

No Headlines